- Home
- PCRX
as of 12-16-2025 11:37am EST
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | 1.0B | IPO Year: | 2011 |
| Target Price: | $32.86 | AVG Volume (30 days): | 723.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.47 | EPS Growth: | N/A |
| 52 Week Low/High: | $18.17 - $27.64 | Next Earning Date: | 11-06-2025 |
| Revenue: | $716,791,000 | Revenue Growth: | 3.14% |
| Revenue Growth (this year): | 6.24% | Revenue Growth (next year): | 9.53% |
AI-Powered PCRX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Pacira BioSciences Inc. (PCRX)
Chief Financial Officer
Avg Cost/Share
$25.14
Shares
9,104
Total Value
$228,874.56
Owned After
56,250
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$25.03
Shares
15,896
Total Value
$397,876.88
Owned After
56,250
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$24.09
Shares
3,960
Total Value
$95,396.40
Owned After
178,367.009
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$22.09
Shares
12,060
Total Value
$266,405.40
Owned After
56,250
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Cross Shawn | PCRX | Chief Financial Officer | Dec 10, 2025 | Sell | $25.14 | 9,104 | $228,874.56 | 56,250 | |
| Cross Shawn | PCRX | Chief Financial Officer | Dec 9, 2025 | Sell | $25.03 | 15,896 | $397,876.88 | 56,250 | |
| SLONIN JONATHAN | PCRX | Chief Medical Officer | Nov 17, 2025 | Sell | $24.09 | 3,960 | $95,396.40 | 178,367.009 | |
| Cross Shawn | PCRX | Chief Financial Officer | Nov 10, 2025 | Sell | $22.09 | 12,060 | $266,405.40 | 56,250 |
Compare PCRX vs Leading Stocks
See how PCRX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PCRX Pacira BioSciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.